Predict your next investment

Jenscare Biotechnology company logo
HEALTHCARE | Biotechnology
jenscare.com

See what CB Insights has to offer

Founded Year

2011

Stage

Series B | Alive

Total Raised

$9.42M

About Jenscare Biotechnology

Jenscare Biotechnology focuses on R&D, production, sales, and services of minimally invasive interventional treatment of valves, and strives to provide solutions for doctors and patients.

Jenscare Biotechnology Headquarter Location

No. 5 building, Zone 777 Binhai four Road, Binhai New District

Ningbo, Zhejiang ,

China

+86 0574-63935666

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Jenscare Biotechnology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Jenscare Biotechnology is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

M

Medical Devices

8,341 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharmaceuticals

5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.